Key result
(Pro)renin receptor blocker (PRRB) reduced retinal leukostasis and expression of VEGF and phosphorylated ERK1/2 in diabetic rodent models partly independent of angiotensin II.
Why the study?
Does (pro)renin receptor blockade reduce retinal leukostasis and inflammatory/angiogenic signaling in experimental diabetic retinopathy?
Does (pro)renin receptor blockade reduce retinal leukostasis and inflammatory/angiogenic signaling in experimental diabetic retinopathy?
Answers are grounded in this paper and cite their sources.
Preclinical evidence suggests that prorenin and the (pro)renin receptor contribute to diabetic retinopathy through both angiotensin II-dependent and independent mechanisms, representing a potential novel therapeutic target despite unresolved questions regarding peptide specificity and in vivo concentrations.
Many lines of evidence implicate the renin-angiotensin system in the pathogenesis of diabetic retinopathy. A recent multicenter trial showed that angiotensin II type 1 (AT1) receptor blockade (ARB) reduced the incidence of retinopathy in type 1 diabetic patients and improved the regression of retinal disease in type 2 diabetic patients (1,2). However, the failure of ARB to prevent progression of diabetic retinopathy indicates a role for mechanisms additional to angiotensin II in its pathogenesis. In this issue of Diabetes , Satofuka et al. (3) provide evidence that prorenin and the (pro)renin receptor, acting in part through mechanisms unrelated to angiotensin II, may contribute to the pathogenesis of diabetic retinopathy. This evidence holds promise for new therapies for diabetic retinopathy and other complications of diabetes. Prorenin is a high–molecular weight biosynthetic precursor of renin. It has a low intrinsic activity of <2% of the activity of renin (4) because it has an amino-terminal 43–amino acid prosegment that masks the active site, thereby preventing access by the renin substrate—angiotensinogen. Renal juxtaglomerular cells are the only known site of renin production, whereas the kidney and a number of extrarenal tissues including adrenal, ovary, testis, placenta, and retina produce prorenin (5–7). Plasma prorenin concentrations are ∼10- to 20-fold higher than those of renin (4). Prorenin concentrations in plasma and vitreous fluid are increased in diabetic subjects (6,8), and plasma prorenin is a powerful marker for both prevalent and incident microvascular complications of diabetes, including nephropathy, retinopathy, and …
No takes yet. Share an insight, caveat, or question.
Wilkinson‐Berka et al. (2009) conducted an editorial in Diabetic retinopathy. (Pro)renin receptor blocker (PRRB) / handle region peptide (HRP) vs. Losartan or heated PRRB control was evaluated on Retinal leukostasis and retinal expression of VEGF, ICAM-1, and phosphorylated ERK1/2. (Pro)renin receptor blocker (PRRB) reduced retinal leukostasis and expression of VEGF and phosphorylated ERK1/2 in diabetic rodent models partly independent of angiotensin II.
Synapse has enriched 10 related papers. Consider them for comparative context: